Frontiers in Public Health
Cost-utility analysis of loxenatide versus DPP-4 inhibitors in Chinese patients with type 2 diabetes at high cardiovascular risk
Computational studyInterventions
Papers by Longbing Lai
2 results
- Frontiers in Pharmacology
Cost-utility analysis of simultaneous initiation of finerenone and empagliflozin for type 2 diabetes mellitus complicated with chronic kidney disease
Computational studyInterventions